The immunogenic part of infliximab is the F(ab′)2, but measuring antibodies to the intact infliximab molecule is more clinically useful

Gut

Volumn 60, Issue 1, 2011, Pages 41-48

  Ben Horin, Shomron ^a   Yavzori, Miri ^a   Katz, Lior ^a   Kopylov, Uri ^a   Picard, Orit ^a   Fudim, Ella ^a   Coscas, Daniel ^a   Bar Meir, Simon ^a   Goldstein, Itamar ^a   Chowers, Yehuda ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; HYDROCORTISONE; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN G1; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DRUG BLOOD LEVEL; DRUG HYPERSENSITIVITY; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; REMISSION; SERUM; TREATMENT RESPONSE; WESTERN BLOTTING;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; BIOTINYLATION; DRUG MONITORING; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; RECEPTORS, IMMUNOLOGIC; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 78651237721     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2009.201533     Document Type: Article

References (18)

1. Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007;56:1226-31. (Pubitemid 47300423)
2. Gisbert JP, Panés J. Loss of response and requirement of Infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009;104:760-7.
3. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of Infliximab in Crohn's disease. N Engl J Med 2003;348:601-8. (Pubitemid 36204954)
4. Farrell RJ, Alsahli M, Jeen YT, et al. Intravenous hydrocortisone premedication reduces antibodies to Infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003;124:917-24. (Pubitemid 36389794)
5. Ainsworth MA, Bendtzen K, Brynskov J. Tumor necrosis factor-alpha binding capacity and anti-Infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of Infliximab in Crohn's disease. Am J Gastroenterol 2008;103:944-8.
6. Wolbink GJ, Vis M, Lems W, et al. Development of antiInfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:711-15.
7. Bendtzen K, Geborek P, Svenson M, et al. Individualized monitoring of drug bioavailability and immunogenecity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum 2006;54:3782-9.
8. St Clair EW, Wagner CL, Fasanmade AA, et al. The relationship of serum Infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:1451-9.
9. Svenson M, Geborek P, Saxne T, et al. Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum Infliximab and anti-Infliximab antibodies. Rheumatology 2007;46:1828-34. (Pubitemid 350168300)
10. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004;126:402-13.
11. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004;2:542-53.
12. Bendtzen K, Ainsworth M, Steenholdt C, et al. Individual medicine in inflammatory bowel disease: Monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Scand J Gastroenterol 2009;13:1-8.
13. Magdelaine-Beuzelin C, Vermeire S, Goodall M, et al. IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab. Pharmacogenet Genomics 2009;19:383-7.
14. Candon S, Mosca A, Ruemmele F, et al. Clinical and biological consequences of immunization to Infliximab in pediatric Crohn's disease. Clin Immunol 2006;118:11-19.
15. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled Infliximab maintenance: a randomized trial. Gastroenterology 2008;134:1861-8. (Pubitemid 351790744)
16. Miyakawa H, Tanaka A, Kikuchi K, et al. Detection of antimitochondrial autoantibodies in immunofluorescent AMA-negative patients with primary biliary cirrhosis using recombinant autoantigens. Hepatology 2001;34:243-8.
17. Waqqas A, Loftus EV, Faubion WA, et al. Clinical utility of measuring infliximab and human-anti-chimeric antibody level in patients with inflammatory bowel disease. Gastroenterology 2009;136(Suppl 1):A-147.
18. Louis E, Vernier-Massouille G, Grimaud JC, et al. Infliximab Discontinuation in Crohn's disease patients in stable remission on combined therapy with immunosuppressors: a prospective ongoing cohort Study. Gastroenterology 2009;136(Suppl 1):A-146.